MedTrace Logo

R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

NCT00140218 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-01-08

No results posted yet for this study

Summary

The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.

Conditions

Interventions

DRUG

R(+) pramipexole dihydrochloride monohydrate

10 mg tid oral

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • Bennett, James P., Jr., M.D., Ph.D.

    lead INDIV

Principal Investigators

  • Lawrence H Phillips, M.D. · University of Virginia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2007-01-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00140218 on ClinicalTrials.gov